Katsiaryna Bykov, Pharm.D., Sc.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Drug Interactions | 11 | 2021 | 1416 | 2.400 |
Why?
|
| Tramadol | 2 | 2024 | 60 | 1.820 |
Why?
|
| Cross-Over Studies | 4 | 2020 | 2078 | 1.410 |
Why?
|
| Analgesics, Opioid | 10 | 2024 | 3808 | 1.280 |
Why?
|
| Warfarin | 6 | 2023 | 1483 | 1.160 |
Why?
|
| Venous Thromboembolism | 3 | 2023 | 1866 | 0.980 |
Why?
|
| Phenylpropionates | 1 | 2024 | 35 | 0.930 |
Why?
|
| Ticlopidine | 3 | 2017 | 730 | 0.830 |
Why?
|
| Liver Function Tests | 1 | 2024 | 523 | 0.830 |
Why?
|
| Pyridazines | 1 | 2024 | 202 | 0.820 |
Why?
|
| Oxycodone | 2 | 2022 | 139 | 0.760 |
Why?
|
| Anticoagulants | 7 | 2023 | 4812 | 0.760 |
Why?
|
| Rhabdomyolysis | 2 | 2019 | 152 | 0.730 |
Why?
|
| Pharmacoepidemiology | 2 | 2023 | 350 | 0.710 |
Why?
|
| Urinary Tract Infections | 3 | 2024 | 802 | 0.700 |
Why?
|
| Platelet Aggregation Inhibitors | 3 | 2024 | 2751 | 0.690 |
Why?
|
| Drug Evaluation | 2 | 2020 | 641 | 0.690 |
Why?
|
| Adrenergic beta-1 Receptor Antagonists | 1 | 2018 | 30 | 0.630 |
Why?
|
| Thalidomide | 1 | 2024 | 885 | 0.630 |
Why?
|
| Metoprolol | 1 | 2018 | 90 | 0.610 |
Why?
|
| Pain, Postoperative | 5 | 2021 | 1739 | 0.580 |
Why?
|
| Hemophilia B | 1 | 2017 | 84 | 0.570 |
Why?
|
| Drug Utilization | 3 | 2020 | 1188 | 0.570 |
Why?
|
| Factor VIIa | 1 | 2017 | 103 | 0.560 |
Why?
|
| Antithrombins | 2 | 2019 | 294 | 0.560 |
Why?
|
| Cardiovascular Agents | 4 | 2015 | 840 | 0.550 |
Why?
|
| Pyridones | 1 | 2022 | 809 | 0.540 |
Why?
|
| Data Mining | 1 | 2021 | 551 | 0.530 |
Why?
|
| Epidemiologic Research Design | 1 | 2019 | 368 | 0.530 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 3 | 2024 | 311 | 0.500 |
Why?
|
| Blood Coagulation Factors | 1 | 2017 | 365 | 0.500 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 4 | 2019 | 3245 | 0.480 |
Why?
|
| Databases, Factual | 13 | 2024 | 7967 | 0.460 |
Why?
|
| Hemophilia A | 1 | 2017 | 360 | 0.460 |
Why?
|
| Medication Adherence | 5 | 2018 | 2176 | 0.450 |
Why?
|
| Cohort Studies | 21 | 2024 | 41487 | 0.430 |
Why?
|
| Research Design | 4 | 2021 | 6180 | 0.430 |
Why?
|
| Myocardial Infarction | 6 | 2018 | 11460 | 0.430 |
Why?
|
| Hemorrhage | 4 | 2023 | 3424 | 0.410 |
Why?
|
| Insurance, Health | 3 | 2024 | 2498 | 0.410 |
Why?
|
| Hypoglycemic Agents | 5 | 2024 | 3085 | 0.390 |
Why?
|
| Hyperkalemia | 2 | 2024 | 233 | 0.390 |
Why?
|
| Electronic Health Records | 2 | 2019 | 4811 | 0.380 |
Why?
|
| Pyrazoles | 1 | 2022 | 2009 | 0.380 |
Why?
|
| Suicide | 1 | 2022 | 1601 | 0.380 |
Why?
|
| Thromboembolism | 1 | 2017 | 995 | 0.370 |
Why?
|
| United States | 21 | 2024 | 72334 | 0.350 |
Why?
|
| Clarithromycin | 2 | 2020 | 86 | 0.340 |
Why?
|
| Fluoroquinolones | 2 | 2022 | 307 | 0.330 |
Why?
|
| Azithromycin | 2 | 2022 | 199 | 0.330 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2016 | 1116 | 0.330 |
Why?
|
| Inpatients | 1 | 2021 | 2548 | 0.320 |
Why?
|
| Middle Aged | 31 | 2024 | 220895 | 0.320 |
Why?
|
| Cytochrome P-450 CYP3A | 2 | 2019 | 114 | 0.320 |
Why?
|
| Aged | 30 | 2024 | 169289 | 0.320 |
Why?
|
| Case-Control Studies | 5 | 2024 | 22176 | 0.290 |
Why?
|
| Medicare | 4 | 2023 | 6770 | 0.290 |
Why?
|
| Humans | 60 | 2024 | 761504 | 0.290 |
Why?
|
| Cholesterol | 1 | 2016 | 2904 | 0.280 |
Why?
|
| United States Food and Drug Administration | 3 | 2024 | 1664 | 0.280 |
Why?
|
| Prescription Drugs | 3 | 2024 | 631 | 0.280 |
Why?
|
| Propensity Score | 9 | 2024 | 1913 | 0.270 |
Why?
|
| Treatment Failure | 1 | 2012 | 2645 | 0.270 |
Why?
|
| Data Collection | 1 | 2015 | 3322 | 0.270 |
Why?
|
| Cerebral Hemorrhage | 2 | 2016 | 2656 | 0.260 |
Why?
|
| Opioid-Related Disorders | 1 | 2020 | 2164 | 0.260 |
Why?
|
| Healthcare Disparities | 3 | 2016 | 3358 | 0.260 |
Why?
|
| Female | 36 | 2024 | 392644 | 0.240 |
Why?
|
| Patient Readmission | 1 | 2018 | 3270 | 0.230 |
Why?
|
| Baclofen | 2 | 2022 | 120 | 0.230 |
Why?
|
| Male | 32 | 2024 | 360804 | 0.230 |
Why?
|
| Adult | 21 | 2024 | 221177 | 0.220 |
Why?
|
| Respiratory Aspiration | 1 | 2024 | 89 | 0.220 |
Why?
|
| Parkinson Disease | 2 | 2016 | 2877 | 0.210 |
Why?
|
| Norfloxacin | 1 | 2022 | 24 | 0.210 |
Why?
|
| Carisoprodol | 1 | 2022 | 5 | 0.210 |
Why?
|
| Methocarbamol | 1 | 2022 | 8 | 0.210 |
Why?
|
| Drug Substitution | 2 | 2016 | 290 | 0.200 |
Why?
|
| Urinary Bladder, Overactive | 1 | 2024 | 115 | 0.200 |
Why?
|
| Drug Labeling | 1 | 2024 | 248 | 0.200 |
Why?
|
| Delivery of Health Care | 1 | 2019 | 5336 | 0.190 |
Why?
|
| Paroxetine | 1 | 2022 | 182 | 0.190 |
Why?
|
| Methods | 1 | 2021 | 1067 | 0.190 |
Why?
|
| Product Surveillance, Postmarketing | 2 | 2015 | 452 | 0.190 |
Why?
|
| Diabetes Mellitus | 1 | 2019 | 5840 | 0.180 |
Why?
|
| Hospitalization | 6 | 2022 | 10723 | 0.180 |
Why?
|
| Ciprofloxacin | 1 | 2022 | 312 | 0.180 |
Why?
|
| Neuromuscular Agents | 1 | 2022 | 147 | 0.180 |
Why?
|
| Coronary Artery Bypass | 3 | 2015 | 2188 | 0.180 |
Why?
|
| Lorazepam | 1 | 2021 | 154 | 0.180 |
Why?
|
| Epidemiology | 1 | 2023 | 279 | 0.180 |
Why?
|
| Drugs, Generic | 2 | 2016 | 448 | 0.170 |
Why?
|
| Quality-Adjusted Life Years | 3 | 2015 | 1722 | 0.170 |
Why?
|
| Drug Therapy, Combination | 4 | 2020 | 6310 | 0.170 |
Why?
|
| Stroke | 3 | 2017 | 9757 | 0.170 |
Why?
|
| Retrospective Studies | 10 | 2023 | 80636 | 0.170 |
Why?
|
| Time Factors | 5 | 2022 | 39967 | 0.170 |
Why?
|
| Control Groups | 1 | 2019 | 104 | 0.170 |
Why?
|
| Insurance Claim Review | 2 | 2021 | 741 | 0.160 |
Why?
|
| Postoperative Period | 2 | 2021 | 1813 | 0.150 |
Why?
|
| Simvastatin | 1 | 2020 | 346 | 0.150 |
Why?
|
| Hospitals | 2 | 2022 | 3882 | 0.150 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2024 | 874 | 0.150 |
Why?
|
| Fluoxetine | 1 | 2022 | 733 | 0.150 |
Why?
|
| Computer Simulation | 3 | 2020 | 6240 | 0.150 |
Why?
|
| Health Services | 1 | 2022 | 752 | 0.140 |
Why?
|
| Diabetes Mellitus, Type 2 | 4 | 2024 | 12148 | 0.140 |
Why?
|
| Anti-Bacterial Agents | 3 | 2022 | 7407 | 0.140 |
Why?
|
| Hip Fractures | 1 | 2024 | 988 | 0.130 |
Why?
|
| Osteoarthritis | 1 | 2024 | 1063 | 0.130 |
Why?
|
| Aortic Aneurysm | 1 | 2020 | 648 | 0.130 |
Why?
|
| Names | 1 | 2015 | 54 | 0.130 |
Why?
|
| Risk Factors | 11 | 2024 | 74206 | 0.130 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2015 | 2273 | 0.120 |
Why?
|
| Parkinson Disease, Secondary | 1 | 2015 | 122 | 0.120 |
Why?
|
| Delayed-Action Preparations | 1 | 2018 | 962 | 0.120 |
Why?
|
| Community Pharmacy Services | 1 | 2014 | 52 | 0.120 |
Why?
|
| Ketorolac | 1 | 2015 | 94 | 0.120 |
Why?
|
| Antihypertensive Agents | 1 | 2024 | 2024 | 0.120 |
Why?
|
| Administration, Oral | 1 | 2022 | 4021 | 0.110 |
Why?
|
| Young Adult | 8 | 2024 | 59243 | 0.110 |
Why?
|
| Comparative Effectiveness Research | 2 | 2023 | 709 | 0.110 |
Why?
|
| Information Systems | 1 | 2015 | 396 | 0.110 |
Why?
|
| Hypertension, Pulmonary | 1 | 2024 | 1578 | 0.110 |
Why?
|
| Prevalence | 2 | 2021 | 15732 | 0.110 |
Why?
|
| Models, Theoretical | 2 | 2015 | 3575 | 0.110 |
Why?
|
| Renal Insufficiency, Chronic | 2 | 2024 | 2243 | 0.110 |
Why?
|
| Anti-Ulcer Agents | 1 | 2013 | 112 | 0.100 |
Why?
|
| Myocardial Revascularization | 1 | 2016 | 790 | 0.100 |
Why?
|
| Thrombophilia | 1 | 2015 | 305 | 0.100 |
Why?
|
| Osteoarthritis, Hip | 1 | 2017 | 409 | 0.100 |
Why?
|
| Thiazolidinediones | 1 | 2015 | 461 | 0.100 |
Why?
|
| Suicidal Ideation | 1 | 2022 | 1447 | 0.100 |
Why?
|
| Histamine H2 Antagonists | 1 | 2013 | 166 | 0.100 |
Why?
|
| Logistic Models | 4 | 2020 | 13255 | 0.100 |
Why?
|
| Algorithms | 1 | 2012 | 14031 | 0.100 |
Why?
|
| Proportional Hazards Models | 4 | 2020 | 12463 | 0.100 |
Why?
|
| Cephalosporins | 1 | 2013 | 198 | 0.100 |
Why?
|
| Tamoxifen | 1 | 2016 | 965 | 0.100 |
Why?
|
| Fractures, Bone | 1 | 2024 | 2046 | 0.100 |
Why?
|
| Financing, Personal | 1 | 2014 | 309 | 0.100 |
Why?
|
| Reminder Systems | 1 | 2014 | 388 | 0.100 |
Why?
|
| Recurrence | 2 | 2022 | 8465 | 0.090 |
Why?
|
| Hyperlipidemias | 1 | 2016 | 771 | 0.090 |
Why?
|
| Comorbidity | 3 | 2022 | 10508 | 0.090 |
Why?
|
| Enterocolitis, Pseudomembranous | 1 | 2013 | 264 | 0.090 |
Why?
|
| Atrial Fibrillation | 2 | 2023 | 5127 | 0.090 |
Why?
|
| Prescriptions | 2 | 2024 | 386 | 0.090 |
Why?
|
| Emergency Medical Services | 1 | 2022 | 1923 | 0.090 |
Why?
|
| Neoplasms | 1 | 2019 | 22170 | 0.090 |
Why?
|
| Benzodiazepines | 3 | 2022 | 1132 | 0.080 |
Why?
|
| Vancomycin | 1 | 2013 | 503 | 0.080 |
Why?
|
| Treatment Outcome | 6 | 2019 | 64680 | 0.080 |
Why?
|
| Evidence-Based Medicine | 1 | 2020 | 3688 | 0.080 |
Why?
|
| Aged, 80 and over | 4 | 2024 | 58976 | 0.080 |
Why?
|
| Proton Pump Inhibitors | 1 | 2013 | 532 | 0.080 |
Why?
|
| Dementia | 1 | 2023 | 2686 | 0.080 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2016 | 1520 | 0.080 |
Why?
|
| Sepsis | 1 | 2022 | 2585 | 0.080 |
Why?
|
| Bone Density Conservation Agents | 1 | 2015 | 795 | 0.080 |
Why?
|
| Recombinant Proteins | 1 | 2017 | 6534 | 0.070 |
Why?
|
| Odds Ratio | 1 | 2020 | 9646 | 0.070 |
Why?
|
| Substance-Related Disorders | 2 | 2022 | 4420 | 0.070 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2013 | 636 | 0.070 |
Why?
|
| Bayes Theorem | 1 | 2015 | 2330 | 0.070 |
Why?
|
| Adolescent | 6 | 2024 | 88319 | 0.070 |
Why?
|
| Cesarean Section | 1 | 2016 | 1396 | 0.070 |
Why?
|
| Pneumonia | 2 | 2020 | 2143 | 0.070 |
Why?
|
| Pain | 1 | 2022 | 5073 | 0.070 |
Why?
|
| Osteoarthritis, Knee | 1 | 2017 | 1234 | 0.070 |
Why?
|
| Arthroplasty, Replacement, Hip | 1 | 2017 | 1413 | 0.070 |
Why?
|
| Drug Prescriptions | 1 | 2016 | 1670 | 0.070 |
Why?
|
| Arthroplasty, Replacement, Knee | 1 | 2017 | 1393 | 0.070 |
Why?
|
| Multiple Myeloma | 1 | 2024 | 5146 | 0.070 |
Why?
|
| Emergency Service, Hospital | 2 | 2022 | 7879 | 0.060 |
Why?
|
| Residence Characteristics | 1 | 2015 | 2093 | 0.060 |
Why?
|
| Risk | 1 | 2017 | 9610 | 0.060 |
Why?
|
| Patient Discharge | 1 | 2018 | 3443 | 0.060 |
Why?
|
| Incidence | 3 | 2020 | 21353 | 0.060 |
Why?
|
| Victoria | 1 | 2024 | 64 | 0.060 |
Why?
|
| Health Status Disparities | 1 | 2016 | 1852 | 0.060 |
Why?
|
| Decision Support Techniques | 1 | 2015 | 1998 | 0.060 |
Why?
|
| Models, Statistical | 1 | 2019 | 5079 | 0.060 |
Why?
|
| Pregnancy | 2 | 2024 | 29874 | 0.060 |
Why?
|
| Self Report | 1 | 2015 | 3724 | 0.060 |
Why?
|
| Cross Infection | 1 | 2013 | 1422 | 0.060 |
Why?
|
| Surgical Wound Infection | 1 | 2013 | 1527 | 0.060 |
Why?
|
| Seizures | 1 | 2016 | 2957 | 0.050 |
Why?
|
| Cross-Sectional Studies | 1 | 2024 | 26125 | 0.050 |
Why?
|
| Orphenadrine | 1 | 2022 | 4 | 0.050 |
Why?
|
| Chlorzoxazone | 1 | 2022 | 7 | 0.050 |
Why?
|
| Drug Administration Schedule | 3 | 2017 | 4853 | 0.050 |
Why?
|
| Hydrocodone | 1 | 2022 | 48 | 0.050 |
Why?
|
| Amitriptyline | 1 | 2022 | 112 | 0.050 |
Why?
|
| Depression | 1 | 2022 | 8124 | 0.050 |
Why?
|
| Socioeconomic Factors | 1 | 2015 | 7827 | 0.050 |
Why?
|
| Epilepsy | 1 | 2016 | 3290 | 0.050 |
Why?
|
| Molecular Epidemiology | 1 | 2023 | 469 | 0.050 |
Why?
|
| Muscle Relaxants, Central | 1 | 2021 | 93 | 0.040 |
Why?
|
| Smoking | 2 | 2016 | 9053 | 0.040 |
Why?
|
| Risk Assessment | 6 | 2021 | 23995 | 0.040 |
Why?
|
| Infant, Newborn | 2 | 2017 | 26198 | 0.040 |
Why?
|
| Child, Preschool | 3 | 2017 | 42230 | 0.040 |
Why?
|
| Follow-Up Studies | 2 | 2017 | 39106 | 0.040 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 2021 | 448 | 0.040 |
Why?
|
| Sodium | 1 | 2024 | 1588 | 0.040 |
Why?
|
| Infant | 2 | 2017 | 36192 | 0.040 |
Why?
|
| Cardiovascular Diseases | 2 | 2014 | 15500 | 0.040 |
Why?
|
| Narcotic Antagonists | 1 | 2022 | 585 | 0.040 |
Why?
|
| Mental Disorders | 1 | 2016 | 6845 | 0.030 |
Why?
|
| Health Services Accessibility | 1 | 2014 | 5440 | 0.030 |
Why?
|
| Community Health Planning | 1 | 2016 | 164 | 0.030 |
Why?
|
| Etodolac | 1 | 2015 | 19 | 0.030 |
Why?
|
| Child | 3 | 2017 | 80153 | 0.030 |
Why?
|
| Insurance Coverage | 2 | 2015 | 1940 | 0.030 |
Why?
|
| Hypnotics and Sedatives | 1 | 2021 | 1179 | 0.030 |
Why?
|
| Lactones | 1 | 2015 | 317 | 0.030 |
Why?
|
| New Jersey | 1 | 2013 | 295 | 0.030 |
Why?
|
| Sulfones | 1 | 2015 | 448 | 0.030 |
Why?
|
| Polypharmacy | 1 | 2015 | 306 | 0.030 |
Why?
|
| Pharmaceutical Preparations | 1 | 2021 | 1089 | 0.030 |
Why?
|
| Health Services Misuse | 1 | 2014 | 244 | 0.020 |
Why?
|
| Embolism | 1 | 2015 | 399 | 0.020 |
Why?
|
| Peptic Ulcer | 1 | 2013 | 217 | 0.020 |
Why?
|
| Pennsylvania | 1 | 2013 | 613 | 0.020 |
Why?
|
| Back Pain | 1 | 2016 | 545 | 0.020 |
Why?
|
| Glucose | 1 | 2024 | 4346 | 0.020 |
Why?
|
| Insurance, Pharmaceutical Services | 1 | 2014 | 348 | 0.020 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2014 | 431 | 0.020 |
Why?
|
| Telephone | 1 | 2014 | 627 | 0.020 |
Why?
|
| Multivariate Analysis | 2 | 2016 | 12059 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2013 | 15631 | 0.020 |
Why?
|
| Age Distribution | 1 | 2016 | 2880 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 2016 | 21012 | 0.020 |
Why?
|
| Postoperative Care | 1 | 2015 | 1468 | 0.020 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2014 | 1241 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2013 | 2927 | 0.020 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2014 | 1516 | 0.020 |
Why?
|
| Drug Monitoring | 1 | 2013 | 962 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2016 | 6343 | 0.020 |
Why?
|
| Anticonvulsants | 1 | 2016 | 1906 | 0.020 |
Why?
|
| Stress, Physiological | 1 | 2013 | 1403 | 0.020 |
Why?
|
| Antidepressive Agents | 1 | 2016 | 2897 | 0.010 |
Why?
|
| Migraine Disorders | 1 | 2016 | 1701 | 0.010 |
Why?
|
| Length of Stay | 1 | 2017 | 6425 | 0.010 |
Why?
|
| Brain Ischemia | 1 | 2015 | 3049 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2013 | 10766 | 0.010 |
Why?
|
| Prospective Studies | 2 | 2015 | 54425 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2013 | 10209 | 0.010 |
Why?
|